Roth/MKM analyst Bill Kirk upgraded Tilray (NASDAQ: TLRY) from Neutral to Buy with a price target of $10.00.

The analyst comments: "We are upgrading TLRY shares to Buy: 1) Core Canadian business is steady; 2) International inflecting; 3) CC Pharma has become an advantageous asset; 4) Beverage category improving; 5) Cost savings from Brew Dog are substantial; 6) Share issuance is slowing; and 7) Cost of capital advantages. TLRY shares are back at July 2025 levels (where mgmt was buyers). Since then, the fundamental outlook has improved and the potential for regulatory change is greater. We upgrade TLRY from Neutral to Buy and maintain our $10 PT (~12x EV/EBITDA vs. current ~8x)."

For an analyst ratings summary and ratings history on Tilray click here. For more ratings news on Tilray click here.

Shares of Tilray closed at $6.14 yesterday.